Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Revenue: 2014-2025

Historic Revenue for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to $70.6 million.

  • Viridian Therapeutics, Inc.\DE's Revenue rose 81958.14% to $70.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.8 million, marking a year-over-year increase of 23340.07%. This contributed to the annual value of $302,000 for FY2024, which is 3.82% down from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Revenue stood at $70.6 million, which was up 93,993.33% from $75,000 recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Revenue registered a high of $70.6 million during Q3 2025, and its lowest value of $72,000 during Q2 2023.
  • Its 3-year average for Revenue is $6.5 million, with a median of $72,000 in 2025.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Revenue tumbled by 93.97% in 2023 and then skyrocketed by 81,958.14% in 2025.
  • Quarterly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Revenue stood at $214,000 in 2021, then crashed by 50.93% to $105,000 in 2022, then slumped by 31.43% to $72,000 in 2023, then remained steady at $72,000 in 2024, then surged by 81,958.14% to $70.6 million in 2025.
  • Its last three reported values are $70.6 million in Q3 2025, $75,000 for Q2 2025, and $72,000 during Q1 2025.